Please Note: This trial is no longer enrolling new participants
A phase 3, randomised, multi-centre, open-label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC)
| Protocol No. | CTO-000434 | Scope | National |
|---|---|---|---|
| Principal Investigator | Hristos Kaimakliotis | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
